IDH2 and angioimmunoblastic T-cell lymphoma: Moreover, IDH mutations are detected in many other malignancies, such as chondrosarcoma (50%), acute myeloid leukemia (AML; 30%), cholangiocarcinoma (20%), angioimmunoblastic T-cell lymphoma (AITL), solid papillary carcinoma with reverse polarity (SPCRP), melanoma, breast cancer, etc. [9].